

# Orphan drugs – Rare diseases

Unilabs is a preferred  
Bioanalytical Laboratory Partner  
to the pharma industry in Orphan  
Drugs and Rare Diseases – and  
a leader in precision medicine  
testing for therapeutic drug  
monitoring



Unilabs has a broad range of experience in providing services within Orphan Drugs and Rare Diseases. Examples include – but are not limited to:

- Bioanalytical partner for the first registered European gene therapy for a rare disease
- Bioanalytical partner for an orphan drug replacement enzyme
- GMO approved laboratory facilities
- Testing of immunogenicity directed towards viral vectors (AAV)
- Molecular genetic diagnostics
- Regulatory consultancy in relation to method validation
- Easy transfer of projects between different Centres of Excellence (CoE) via our individually assigned project managers. CoE's include immunoassays, molecular diagnostics, flow cytometry, histopathology and medical imaging
- Management of centralised and de-centralised Companion Diagnostic (CDx) testing and global, customised logistics
- Tailoring of every project – no matter the number of patients. This ensures you get exactly what is required for the project without unnecessary expenses

**Discover what tailor-made  
solutions really mean**

[www.servingpharma.com](http://www.servingpharma.com)  
[ServingPharma@unilabs.com](mailto:ServingPharma@unilabs.com)